All-cash deal: Gilead Sciences buys Israeli firm for nearly $12B ‎‎‎

The stock increased 1.93% or GBX 5.69 on August 25, reaching GBX 300.69.

Terms of the merger agreement call for a wholly owned subsidiary of Gilead to initiate a tender offer to acquire Kite's outstanding shares. Health care companies are rising after hepatitis C and HIV drug maker Gilead Sciences agreed to buy cancer drug maker Kite Pharma for $11.9 billion. It has underperformed by 38.50% the S&P500. Gilead Sciences has gained 2.6% to $75.74, and Kite Pharma has surged 29% to $178.94. The Granite Investment Advisors Inc holds 79,030 shares with $5.66M value, down from 92,806 last quarter. Mastercard Inc Cl A now has $142.57 billion valuation.

About 27,744 shares traded. Kite Pharma Inc (NASDAQ:KITE) has risen 55.47% since August 28, 2016 and is uptrending. It has outperformed by 51.67% the S&P500. Meanwhile, top losers in the sector included CGG SA (ADR) (NYSE: CGG), down 6 percent, and Zion Oil & Gas, Inc.

Investors sentiment decreased to 0.88 in 2016 Q4. Its down 0.21, from 1.45 in 2016Q3. Advantus Mgmt Incorporated owns 132,497 shares or 0.25% of their U.S. portfolio. Pillar Pacific Cap Management invested in 1.15% or 104,299 shares.

Monday morning, the healthcare shares climbed by 0.40 percent. Howe And Rusling Inc invested 0% in Mattersight Corp (NASDAQ:MATR). Bainco Intll Investors holds 8.77% of its portfolio in Kite Pharma Inc (NASDAQ:KITE) for 1.15 million shares. Signalpoint Asset Llc holds 0.06% in Amgen, Inc. It dived, as 98 investors sold AMGN shares while 488 reduced holdings. Artal Gp holds 250,000 shares or 0.25% of its portfolio.

Since February 28, 2017, it had 0 buys, and 3 insider sales for $22.24 million activity. About 140,817 shares traded. Wells Fargo Mn reported 11.31 million shares stake.

On August 28 the company was changed to "Hold" by BTIG Research which is down from the previous "Buy" rating.

Also in company news, Expedia (EXPE) dropped 4.6% amid multiple media reports its chief executive officer has been selected to lead ride-sharing firm Uber. Deutsche Bank maintained it with "Buy" rating and GBX 775 target in Tuesday, February 9 report. The stock of Morgan Advanced Materials PLC (LON:MGAM) earned "Sell" rating by Panmure Gordon on Friday, September 18. Jefferies maintained the stock with "Hold" rating in Monday, August 21 report. Blackrock Fund reported 49,262 shares. Robert W. Baird restated an "outperform" rating and issued a $87.00 target price on shares of Gilead Sciences in a research note on Wednesday, May 3rd. The company was downgraded on Thursday, March 2 by Citigroup. The firm has "Outperform" rating by RBC Capital Markets given on Wednesday, November 2. Therefore 55% are positive. The company was maintained on Wednesday, June 7 by Cowen & Co. On Tuesday, September 8 the stock rating was initiated by Susquehanna with "Positive".

If axi-cel wins an FDA go ahead, Gilead Sciences cancer revenue could catapult higher. (NASDAQ:GILD) for 3,607 shares. Craig Hallum has "Buy" rating and $6700 target. Needham has "Buy" rating and $125 target. The rating was maintained by UBS on Friday, April 29 with "Buy". Another trade for 5,000 shares valued at $337,392 was sold by Alton Gregg H. The insider, MARTIN JOHN C, now holds 3.13 million shares of GILD. Shares for $668,667 were sold by Cogan John Francis on Tuesday, May 9. Its up 0.02, from 0.91 in 2016Q3. Blackrock Fund invested in 0.02% or 1.99 million shares. S Squared Ltd Liability Corp has 467,927 shares.

There are 1,644 institutional holders with active positions, accounting for 987.09 million shares in total. Swiss Bank & Trust owns 65,250 shares. (NASDAQ:GILD). Partnervest Advisory Ltd Company owns 0.12% invested in Gilead Sciences, Inc. (NASDAQ:GILD). United Cap Advisers Limited Liability reported 234,521 shares.

More notable recent Gilead Sciences, Inc.